SAGE Overview

Acquisition Announcement: Supernus Pharmaceuticals has completed its acquisition of Sage Therapeutics, enhancing its psychiatry portfolio with the FDA-approved ZURZUVAE for postpartum depression and aiming for significant future growth through cost synergies and diversified revenue sources.

Financial Details: The acquisition involved a cash offer of $8.50 per share plus contingent value rights potentially worth up to $3.50, based on specific sales milestones of ZURZUVAE, with 58% of Sage's shares tendered in the offer.

Acquisition Announcement: Supernus Pharmaceuticals has announced the expiration of the waiting period under the HSR Act for its proposed acquisition of Sage Therapeutics, which is set to be completed through a tender offer and subsequent merger.

Offer Details: The tender offer includes a payment of $8.50 per share in cash plus contingent value rights that could yield up to an additional $3.50 per share based on specific sales milestones related to the drug ZURZUVAE.

Marketing Authorization for ZURZUVAE: Biogen Inc. announced that the European Medicines Agency's Committee has recommended marketing authorization for ZURZUVAE, a treatment for postpartum depression in adults, based on positive results from the SKYLARK study.

Next Steps and Significance: The recommendation will be reviewed by the European Commission, with a final decision expected in Q3 2025; if approved, ZURZUVAE will be the first EU-authorized treatment specifically for postpartum depression.

Biogen's ZURZUVAE Approval: Biogen announced that the European Medicines Agency's CHMP has recommended marketing authorization for ZURZUVAE (zuranolone) to treat postpartum depression in adults, potentially making it the first EU-approved treatment specifically for this condition.

Clinical Study Results: The recommendation is based on positive results from the SKYLARK Study, which showed significant reductions in depressive symptoms as early as Day 3 of a 14-day treatment course, with ZURZUVAE being generally well-tolerated by patients.

Investigation of Companies: Halper Sadeh LLC is investigating Sage Therapeutics, Charter Communications, and Vigil Neuroscience for potential violations of federal securities laws and breaches of fiduciary duties related to their recent transactions and mergers.

Legal Support for Shareholders: The firm offers free consultations to shareholders regarding their legal rights and options, aiming to seek increased compensation or additional disclosures on behalf of affected investors.

Investigation of Companies: Halper Sadeh LLC is investigating NV5 Global, Sage Therapeutics, and Olo Inc. for potential violations of federal securities laws related to their proposed sales, offering shareholders various compensation packages.

Legal Support for Shareholders: The firm encourages affected shareholders to contact them for legal rights and options, emphasizing that they operate on a contingent fee basis, meaning no upfront costs for clients.